Ibogaine shows promise for PTSD in veterans, Stanford study finds

Study suggests ibogaine may help veterans with PTSD

A Stanford-led study has found that ibogaine, a psychoactive compound, may offer lasting relief from PTSD, depression, and anxiety for special operations veterans. Published in the journal Translational Psychiatry on August 12, the study followed 30 veterans over a year, revealing sustained improvements in mental health symptoms. However, the study's lack of a control group means the findings cannot definitively attribute these benefits to ibogaine alone.

What the study found

The research involved 30 male veterans with traumatic brain injuries, most of whom had PTSD. They received ibogaine treatment at a clinic in Mexico, accompanied by magnesium infusions to mitigate heart risks. Researchers assessed the participants at intervals over 12 months, with 25 completing the full study. Initial results showed significant reductions in PTSD, depression, and anxiety symptoms, which largely persisted a year later. According to Stanford, the probability of maintaining remission at one year was 84% for PTSD, 66% for depression, and 61% for anxiety.

Limitations and risks

Despite promising results, the study's open-label design and absence of a placebo group limit its conclusions. Participants engaged in various therapies post-treatment, including counseling and other psychedelics, complicating the attribution of benefits solely to ibogaine. Additionally, ibogaine's known heart risks necessitated medical monitoring and magnesium infusions during the study.

Regulatory context

Ibogaine remains a Schedule I drug in the United States, not approved by the FDA for any use. This status compels individuals seeking treatment to travel abroad, as the study participants did. Texas has allocated $50 million for ibogaine clinical trials, aiming for FDA approval, while federal efforts to expedite psychedelic drug reviews are underway.

Why it matters

The study's findings contribute to the ongoing debate about the long-term efficacy of psychedelic treatments for PTSD and other mental health conditions. With increasing interest and funding directed toward psychedelic research, understanding ibogaine's potential benefits and risks is crucial. However, controlled trials are necessary to establish its safety and effectiveness.

While the Stanford study offers preliminary insights, it underscores the need for further research to determine ibogaine's role in treating PTSD and related disorders.